Lataa...

A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer

Mutational testing has moved to the forefront as an integral component in the management of patients with non-small cell lung cancer (NSCLC). Currently there are three targeted therapies (erlotinib, afatinib, and crizotinib) approved by the Food and Drug Administration (FDA) to treat patients with s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Lammers, Philip E., Lovly, Christine M., Horn, Leora
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4151469/
https://ncbi.nlm.nih.gov/pubmed/24453288
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!